Big Ideas on LinkedInTo followicon-youtube

Information Icon Water Mark
 

Add to Offline Folder allows you to add website content to an offline folder for viewing or printing later.

Binder icon image Offline folder

To access your folder, click the Offline Folder link at the top of the page.

 

Solopep

Kevin O'Sullivan, Solopep Ltd

name

Solopep Ltd. is a spin-out company from the University of Limerick (UL) that has developed the world’s first disposable OPEP devices to deliver airway clearance therapy.

Solopep Ltd. is committed to Revolutionising Respiratory Care by developing the world’s first range of disposable Oscillating Positive Expiratory Pressure (OPEP) devices.

OPEP devices are used to remove excess secretions from the respiratory tract, reduce mucus plugging in the small airways, and to improve gas exchange in patients with hypersecretory diseases. Currently, reusable OPEP devices require rigorous daily cleaning to prevent colonisation with potentially harmful pathogens, placing an undue burden and risk on both patients and care-givers..

Up to 40 minutes a day can be spent on cleaning OPEP devices for those at highest risk of infection. Furthermore, these reusable and expensive devices are not compatible with single patient use hospital applications for acute respiratory illnesses or with infection control guidelines.

Our patent protected mechanism allows us to deliver safe, effective airway clearance to patients with Cystic Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), or bronchiectasis in a disposable device.

In comparison to other devices, Solopep delivers the same mechanical performance but in the smallest form factor of any product already on the market. This affords patients greater discretion to carry out airway clearance whenever and wherever it is required.

In two Health Products Regulatory Authority (HPRA) approved studies of patients with cystic fibrosis and COPD, the results of which were recently presented at the European Cystic Fibrosis Society conference, Solopep was shown to be as effective at maintaining pulmonary function as the current market leader. Participants replaced their current device with Solopep for one month, with 100% of patients preferring Solopep to their current device.

Ideally suited to the acute or home setting, Solopep is a cost effective and safe way to deliver airway clearance therapy to patients whether it’s for a day, a month, or a lifetime.

 Previous      Promoters       Next

Companies Attending

  • logo-dlr
  • logo-guitarcentre
  • logo-ohana
  • logo-aquila
  • logo-bruko
  • logo-mercatino
  • logo-ptools
  • logo-ptools

See all Company profiles